David W Barbara1, Joseph A Hyder1, Travis L Behrend1, Martin D Abel1, Hartzell V Schaff2, William J Mauermann3. 1. Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN. 2. Department of Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, MN. 3. Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN. Electronic address: Mauermann.William@mayo.edu.
Abstract
OBJECTIVES: This study's purpose was to review non-cardiac surgery (NCS) in patients with hypertrophic obstructive cardiomyopathy (HOCM) to examine perioperative management and quantify postoperative mortality and worsening heart failure. DESIGN: Retrospective review. SETTING: A single tertiary care center. PARTICIPANTS: The study included 57 adult patients with HOCM who underwent NCS from January 1, 1996, through January 31, 2014. INTERVENTIONS: Noncardiac surgery. MEASUREMENTS AND MAIN RESULTS: The authors identified 57 HOCM patients who underwent 96 NCS procedures. Vasoactive medications were administered to the majority of NCS patients. Three patients (3%) died within 30 days of NCS, but causes of death did not appear to be cardiac in nature. Death after NCS was not significantly associated with preoperative left ventricular ejection fraction (p = 0.2727) or peak instantaneous systolic resting gradient (0.8828), but was associated with emergency surgery (p = 0.0002). Three patients experienced worsening heart failure postoperatively, and this was significantly associated with preoperative New York Heart Association Class III-IV symptoms compared with I-II symptoms (p = 0.0008). CONCLUSIONS: HOCM patients safely can undergo NCS at multidisciplinary centers experienced in caring for these patients. The mortality rate in this study was less than that reported in the majority of other studies. Postoperative complications, including increasing heart failure, may occur, especially in patients with more severe preoperative cardiac symptoms.
OBJECTIVES: This study's purpose was to review non-cardiac surgery (NCS) in patients with hypertrophic obstructive cardiomyopathy (HOCM) to examine perioperative management and quantify postoperative mortality and worsening heart failure. DESIGN: Retrospective review. SETTING: A single tertiary care center. PARTICIPANTS: The study included 57 adult patients with HOCM who underwent NCS from January 1, 1996, through January 31, 2014. INTERVENTIONS: Noncardiac surgery. MEASUREMENTS AND MAIN RESULTS: The authors identified 57 HOCM patients who underwent 96 NCS procedures. Vasoactive medications were administered to the majority of NCS patients. Three patients (3%) died within 30 days of NCS, but causes of death did not appear to be cardiac in nature. Death after NCS was not significantly associated with preoperative left ventricular ejection fraction (p = 0.2727) or peak instantaneous systolic resting gradient (0.8828), but was associated with emergency surgery (p = 0.0002). Three patients experienced worsening heart failure postoperatively, and this was significantly associated with preoperative New York Heart Association Class III-IV symptoms compared with I-II symptoms (p = 0.0008). CONCLUSIONS: HOCM patients safely can undergo NCS at multidisciplinary centers experienced in caring for these patients. The mortality rate in this study was less than that reported in the majority of other studies. Postoperative complications, including increasing heart failure, may occur, especially in patients with more severe preoperative cardiac symptoms.
Authors: José J Arcas Bellas; Cristina Sánchez; Ana González; Alberto Forteza; Verónica López; Javier García Fernández Journal: Saudi J Anaesth Date: 2021-04-01